Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 0.6 %

BTX opened at $6.54 on Friday. The company’s 50 day moving average is $3.25 and its 200-day moving average is $1.69. The company has a market cap of $384.72 million, a P/E ratio of -2.88 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $6.35 and a 1-year high of $8.31.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.